1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Since 2021, shares of (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the past few years. The price drop was justified largely because the company's fate was uncertain. There were question marks relating to its growth and a canceled purchase agreement.
The good news is that one of those issues recently reached a positive resolution. Is that enough to make this beaten-down stock worth taking a chance on?
One of the clouds hanging over Novavax was a dispute with a global vaccine organization called Gavi, the Vaccine Alliance. The issue goes back to 2022 when Novavax terminated a purchase agreement with Gavi after it didn't procure the doses it had previously agreed to buy. Gavi paid $700 million in advance, which it ended up wanting a refund for as the shots weren't needed anymore. But Novavax said the payments were nonrefundable.
Source Fool.com
Novavax Inc. Stock
Based on 3 Buy predictions and 2 Sell predictions the sentiment towards Novavax Inc. is rather balanced.
With a target price of 12 € there is potential for a 215.08% increase which would mean more than doubling the current price of 3.81 € for Novavax Inc..